Claims-linked Survey Study to Assess Burden of Illness Among Patients Treated With LAMA/LABA vs ICS/LABA Single Inhaler Dual Therapy
Phase of Trial: Phase IV
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Sep 2019 Status changed from recruiting to completed.
- 15 Aug 2019 Planned End Date changed from 30 Aug 2019 to 20 Sep 2019.
- 15 Aug 2019 Planned primary completion date changed from 30 Aug 2019 to 20 Sep 2019.